List of Excipients in Branded Drug ULESFIA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Cerecor Inc	ULESFIA	benzyl alcohol	23594-780	CARBOMER HOMOPOLYMER TYPE B	1969-12-31
Cerecor Inc	ULESFIA	benzyl alcohol	23594-780	MINERAL OIL	1969-12-31
Cerecor Inc	ULESFIA	benzyl alcohol	23594-780	POLYSORBATE 80	1969-12-31
Cerecor Inc	ULESFIA	benzyl alcohol	23594-780	SORBITAN MONOOLEATE	1969-12-31
Cerecor Inc	ULESFIA	benzyl alcohol	23594-780	TROLAMINE	1969-12-31
Cerecor Inc	ULESFIA	benzyl alcohol	23594-780	WATER	1969-12-31

Ulesfia Excipient Strategy and Commercial Opportunities for Benzyl Alcohol 5% Lotion

Last updated: August 5, 2026

Ulesfia is a prescription 5% benzyl alcohol lotion for head-lice treatment in patients aged 6 months and older. Its commercial opportunity is driven less by active-ingredient novelty than by formulation performance, pediatric tolerability, ease of rinsing, supply reliability, and regulatory positioning. A competing product can pursue a lower-cost generic pathway, a differentiated topical formulation, or a broader consumer-health strategy, but excipient changes must preserve benzyl alcohol exposure, lice-killing performance, product stability, and the product’s non-ovicidal labeling limitations.

What is Ulesfia and how does its formulation work?

Ulesfia contains benzyl alcohol 5% as the active ingredient. The product is applied to the scalp and hair, left in place for 10 minutes, rinsed with water, and repeated after seven days. Benzyl alcohol immobilizes lice by blocking their respiratory spiracles. It does not reliably kill eggs, which is why repeat treatment is required under the labeled regimen.[1]

Attribute	Ulesfia profile
Brand name	Ulesfia
Active ingredient	Benzyl alcohol 5%
Dosage form	Topical lotion
Indication	Head lice infestation
FDA approval	2009
Minimum labeled age	6 months
Application time	10 minutes
Repeat treatment	Day 9 recommended in the FDA label, following the initial treatment
Prescription status	Prescription drug
Ovicidal activity	No
Primary formulation challenge	Delivering sufficient surface coverage while limiting irritation, runoff, and residue

The commercial product is a rinse-off lotion rather than a shampoo. That distinction affects the excipient strategy. The formulation must wet hair, spread across the scalp, remain in contact during the 10-minute application, and rinse without excessive greasiness or tangling.

What excipients are used in Ulesfia?

The FDA-approved labeling identifies benzyl alcohol as the active ingredient and lists the inactive ingredients used to form the lotion vehicle.[1] Public product information has identified a water-based emulsion or lotion system containing conventional viscosity, emulsification, pH-control, and preservation components.

The most important excipient functions are:

Excipient function	Commercial purpose
Aqueous vehicle	Provides scalp and hair coverage
Emulsifier or surfactant	Supports uniform distribution and rinseability
Thickener or rheology modifier	Limits runoff and improves application control
Humectant	Reduces drying and improves wetting
pH adjuster	Controls skin compatibility and chemical stability
Preservative system	Controls microbial growth during shelf life and in-use handling
Emollient or oil phase	Improves slip, spreadability, and hair feel

Exact composition should be confirmed against the current FDA-approved prescribing information and the relevant manufacturing specification before making formulation, freedom-to-operate, or ANDA decisions. Excipient substitutions can affect comparative quality attributes even when the active concentration remains unchanged.

Which excipient attributes matter most?

The highest-value attributes are rheology, wetting, rinseability, preservative performance, and pediatric tolerability.

A lotion that is too fluid can run from the scalp and create dosing inconsistency. A lotion that is too viscous can resist distribution through dense or curly hair. Surfactants can improve coverage but may increase ocular or scalp irritation. Oil-phase materials can improve slip but may increase residue and complicate rinsing.

The formulation should be assessed using:

• Viscosity across relevant shear rates.
• Spreadability on dry and wet hair.
• Scalp retention during the 10-minute dwell time.
• Rinse time and residual film.
• Hair combability after rinsing.
• Benzyl alcohol content uniformity.
• Preservative effectiveness.
• Freeze-thaw and accelerated stability.
• Microbial limits and container-closure compatibility.
• Ocular and dermal irritation in the intended pediatric population.

What formulation patents protect Ulesfia?

Ulesfia’s principal intellectual-property value is associated with the benzyl alcohol product formulation and its therapeutic use, rather than with a new chemical entity. Patent coverage must be evaluated through the FDA Orange Book, USPTO records, assignment histories, and litigation databases.

The relevant patent categories are:

1. Composition patents covering the benzyl alcohol lotion.
2. Method-of-use patents covering treatment of head lice.
3. Formulation patents covering concentration, vehicle, viscosity, or administration.
4. Manufacturing patents covering emulsion preparation, filling, or stability.
5. Packaging patents covering child-resistant or contamination-limiting delivery systems.

A patent claiming benzyl alcohol 5% in a particular lotion may not block every alternative vehicle. The scope depends on claim construction, especially the definitions of lotion, emulsion, surfactant, viscosity range, pH, and treatment regimen.

What is the Orange Book status of Ulesfia?

Ulesfia was approved under NDA 022257. The Orange Book should be reviewed for current patent listings, expiration dates, pediatric exclusivity, and any reference-product status relevant to an ANDA.[2]

The commercial analysis should separate three issues:

Issue	Relevance
Listed patents	Determine whether a Paragraph IV certification may be required
Regulatory exclusivity	Determine whether FDA can approve an ANDA before the applicable exclusivity expires
Actual enforceability	Determine whether listed claims read on the proposed formulation and use

A patent expiration date alone does not establish generic entry timing. Pediatric exclusivity, litigation, tentative approval, labeling carve-outs, and settlement terms can change the launch date.

When did Ulesfia lose exclusivity?

Ulesfia’s five-year new chemical entity exclusivity did not apply in the same way as it would to a novel active pharmaceutical ingredient because benzyl alcohol was already known and used in pharmaceutical products. The relevant market barriers are therefore patent status, regulatory exclusivity, ANDA review, and commercial execution.

Ulesfia entered the market in 2009. A generic applicant can generally rely on the reference product’s safety and efficacy findings through an ANDA, subject to FDA requirements for pharmaceutical equivalence, bioequivalence where applicable, quality, labeling, and patent certification.[3]

The practical exclusivity timeline is:

Period	Strategic significance
2009 approval	Established the prescription benzyl alcohol 5% product
Patent term	Determined potential Paragraph IV risk and launch constraints
Post-exclusivity period	Opened the market to generic and authorized-generic competition, subject to listed patents
Current market	Differentiation depends on price, distribution, formulation usability, and supply

What generic entry risks exist for Ulesfia?

Generic entry risk is substantial because benzyl alcohol is an established, relatively inexpensive active ingredient and the product is a topical lotion rather than a complex biologic or device-dependent product.

The principal generic strategies are:

ANDA with a pharmaceutically equivalent lotion

The most direct approach is a benzyl alcohol 5% lotion with the same route, dosage form, strength, and therapeutic indication. The applicant would seek approval based on the Ulesfia reference product and demonstrate equivalent quality and performance under FDA requirements.

Key development risks include:

• Demonstrating consistent benzyl alcohol concentration.
• Matching physical characteristics sufficiently for approval.
• Establishing preservative effectiveness.
• Managing differences in inactive ingredients.
• Avoiding patent claims directed to the reference formulation or use.
• Addressing pediatric safety of substituted excipients.

Paragraph IV challenge

If Orange Book-listed patents remain relevant, an ANDA applicant may file a Paragraph IV certification alleging that the patents are invalid, unenforceable, or not infringed. The first substantially complete Paragraph IV applicant may receive 180-day generic exclusivity if statutory requirements are met.[3]

For Ulesfia, patent risk is likely to focus on formulation and method claims rather than active-ingredient composition claims. A noninfringing formulation can reduce litigation exposure, but it may increase comparative quality and regulatory-development complexity.

Authorized generic or branded-generic launch

The rights holder or a commercial partner could launch an authorized generic using the branded product’s formulation, manufacturing process, or labeling structure. This strategy can reduce the revenue available to an independent first generic and create price pressure before multiple ANDA approvals occur.

What excipient strategy can improve Ulesfia’s commercial position?

A differentiated excipient strategy should address use failure, not simply replace ingredients. Head-lice treatment is highly dependent on caregiver application, complete hair coverage, correct dwell time, and repeat dosing.

1. Improve application control

A moderate-yield lotion can reduce dripping and improve scalp coverage. Rheology modifiers should create shear-thinning behavior: the product becomes easier to spread under hand pressure but retains sufficient body at rest.

Potential development targets include:

• Lower runoff from the scalp.
• Better distribution through thick hair.
• Reduced product waste.
• Improved dose consistency.
• Compatibility with pump or squeeze packaging.

2. Improve rinseability

A lower-residue formulation could create a meaningful commercial advantage. Oil-heavy vehicles may improve slip but can leave an undesirable film. A balanced emulsion system can preserve spreadability while reducing the need for repeated shampooing.

Useful performance endpoints include:

• Rinse time.
• Number of shampoo cycles required.
• Residual oil after drying.
• Hair softness and combability.
• Caregiver preference.
• Child acceptability.

3. Reduce irritation potential

Because the product is used on the scalp and hair and may contact the eyes, excipient selection should minimize sensitization and irritation risk. Fragrance-free positioning can improve acceptability in pediatric households, although the absence of fragrance does not by itself establish superior safety.

Preservative selection is especially important. Benzyl alcohol is the active ingredient, so the formulation cannot rely on the active as an ordinary preservative at an independently selected low concentration. The complete system requires microbial challenge testing and stability data.

4. Extend stability and supply resilience

Excipient availability can create a commercial barrier when the product depends on a narrow supplier base. A dual-source strategy for emulsifiers, thickeners, preservatives, and packaging components can reduce supply interruption risk.

Development should evaluate:

• Alternate grades of the same excipient.
• Regional regulatory acceptance.
• Extractables and leachables.
• Container-closure adsorption.
• Viscosity drift over shelf life.
• Benzyl alcohol evaporation or loss.
• Compatibility with high-density polyethylene and laminated tubes.

What commercial opportunities exist beyond a generic Ulesfia lotion?

The strongest opportunities are formulation-led and channel-led rather than based on a new active ingredient.

Opportunity	Commercial rationale	Main barrier
Lower-cost generic	Large addressable market and simple active ingredient	Price erosion and patent review
Premium pediatric lotion	Better rinseability and application experience	Requires evidence and marketing investment
Fragrance-free or low-irritation product	Appeals to caregivers seeking tolerability	Limited differentiation without clinical support
OTC switch strategy	Expands access and consumer reach	FDA monograph, labeling, and safety requirements
International licensing	Leverages established active ingredient	Country-specific registration and trademarks
Institutional or school-health supply	Supports bulk distribution	Procurement pricing and packaging requirements
Combination lice-care kit	Adds comb, conditioner, or treatment accessories	Product classification and consumer claims
Authorized generic	Rapid market entry using established formulation	Channel conflict and margin compression

Can Ulesfia be converted to an over-the-counter product?

An OTC strategy would require FDA review of the active ingredient, concentration, indication, directions, warnings, pediatric use, and consumer labeling. A prescription product cannot be marketed OTC solely because its active ingredient is familiar.

The commercial case would depend on whether the sponsor can support safe self-selection and use by caregivers. The product’s non-ovicidal activity and need for repeat treatment would require clear instructions. Consumer confusion over live lice, eggs, combing, and retreatment could limit the benefit of a switch.

A lower-cost generic prescription product is a more direct opportunity than an OTC conversion.

How does Ulesfia compare with competing lice treatments?

Ulesfia competes with permethrin, pyrethrin-based products, ivermectin lotion, spinosad suspension, malathion lotion, and mechanical nit-removal products. Each has different patent, resistance, dosing, and excipient considerations.

Product category	Active ingredient	Key differentiation	Excipient opportunity
Ulesfia	Benzyl alcohol 5%	Use in patients 6 months and older; short 10-minute dwell time	Rinseability, spreadability, low-irritation vehicle
Permethrin products	Permethrin	Broad availability and low cost	Consumer usability and resistance positioning
Ivermectin lotion	Ivermectin	Different mechanism and dosing profile	Lotion feel and pediatric acceptability
Spinosad suspension	Spinosad	Ovicidal activity and reduced reliance on nit combing	Suspension stability and hair feel
Malathion lotion	Malathion	Prescription treatment with ovicidal claims	Odor, flammability, and tolerability
Mechanical treatment	None	Avoids pesticide exposure	Device design, comb performance, and adherence

Ulesfia’s main weakness is the absence of reliable ovicidal activity. A competing formulation cannot remove that limitation through excipient selection unless the sponsor develops a different active-ingredient product or obtains evidence supporting a new claim.

Which companies are challenging or competing with Ulesfia?

Competition comes from generic manufacturers, branded prescription products, OTC lice-treatment companies, and medical-device suppliers. The relevant companies can change as ANDAs are approved, products are discontinued, or rights are transferred.

A current competitor review should track:

• FDA Drugs@FDA records.
• Orange Book applicant and patent information.
• DailyMed labels.
• ANDA approvals and tentative approvals.
• USPTO assignments.
• District-court and Federal Circuit litigation.
• Retail and institutional distribution listings.

For commercial diligence, the key question is not only whether a competitor has an approved benzyl alcohol 5% product. It is whether the competitor has manufacturing capacity, stable supply, retail access, and a price position that supports rapid substitution.

What manufacturing and intellectual-property barriers affect a new Ulesfia product?

The manufacturing process is relatively accessible compared with sterile injectables or biologics, but topical emulsions still have scale-up risks. Mixing order, shear, temperature, neutralization, and filling conditions can change viscosity and droplet size.

Important process controls include:

• Raw-material identity and grade.
• Emulsion temperature profile.
• Mixing shear and homogenization.
• pH adjustment.
• Deaeration.
• Bulk hold time.
• Fill-weight control.
• Container-closure integrity.
• In-process viscosity and appearance testing.

IP barriers may arise from formulation claims, process claims, packaging claims, trade dress, trademarks, and confidential manufacturing know-how. A design-around should be documented before development begins. The sponsor should also examine whether an excipient substitution creates a new patentable formulation while preserving the reference product’s therapeutic performance.

How strong is the Ulesfia patent estate?

The patent estate should be treated as moderate at most from a technology-barrier perspective because benzyl alcohol is an old active ingredient and the dosage form is a conventional topical lotion. Strength can still exist in narrowly drafted formulation or method claims.

Patent strength depends on:

• Claim breadth.
• Prosecution history.
• Written-description support.
• Enablement.
• Prior-art disclosures.
• Whether the proposed generic uses the claimed excipient system.
• Whether the method claims are relevant to the proposed label.
• Remaining patent term.
• Litigation and settlement history.

A noninfringement position based on a different vehicle may be commercially preferable to a Paragraph IV challenge if the substitute formulation can meet FDA quality and performance expectations at acceptable cost.

Key Takeaways

• Ulesfia is a benzyl alcohol 5% prescription lotion for head lice in patients aged 6 months and older.
• Its commercial value is concentrated in formulation usability, pediatric tolerability, and distribution rather than active-ingredient exclusivity.
• The most attractive excipient targets are rheology, rinseability, wetting, preservation, and hair feel.
• Generic entry risk is meaningful because benzyl alcohol is established and the product is a conventional topical dosage form.
• Patent analysis must distinguish formulation claims, method-of-use claims, manufacturing claims, and current Orange Book listings.
• The strongest commercial pathways are a low-cost ANDA, a premium caregiver-friendly formulation, an authorized generic, or an international licensing program.
• Excipient substitutions can create regulatory, quality, stability, and infringement risks even when the active ingredient and concentration remain unchanged.
• Ulesfia’s lack of reliable ovicidal activity remains a product-level limitation that excipients alone cannot solve.

FAQs

Is benzyl alcohol in Ulesfia an active ingredient or an excipient?

In Ulesfia, benzyl alcohol is the active pediculicidal ingredient at a 5% concentration. It is not being used solely as a preservative.

Can a generic Ulesfia use different inactive ingredients?

Potentially. An ANDA applicant may use different excipients if the product meets applicable FDA requirements for pharmaceutical equivalence, quality, stability, labeling, and safety. Differences must not create unacceptable performance or pediatric tolerability risks.

Does a better rinse-off profile create patent protection?

It can support patentable formulation claims if the claims cover a novel and non-obvious composition or performance-linked formulation. Rinseability alone does not guarantee patentability.

Is Ulesfia ovicidal?

No. The product does not reliably kill lice eggs, which supports the labeled repeat-treatment regimen.[1]

What is the most defensible commercial differentiation for a new benzyl alcohol lotion?

The strongest differentiation is usually measurable caregiver benefit: controlled application, complete scalp coverage, rapid rinsing, reduced residue, low irritation, and consistent supply. Marketing claims should be supported by formulation testing and, where necessary, clinical or human-factors evidence.

References

1. U.S. Food and Drug Administration. (2009). Ulesfia (benzyl alcohol) lotion, 5%: Prescribing information. NDA 022257.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application (ANDA) process and patent certifications.
4. U.S. National Library of Medicine. (n.d.). Ulesfia: Benzyl alcohol lotion, 5%. DailyMed.